Pharma BD Deal Intelligence
On April 11, 2024, Arvinas entered into an exclusive global license agreement with Novartis for the worldwide development and commercialization of ARV-766, its second-generation PROTAC androgen receptor degrader for prostate cancer, together with an asset purchase agreement covering Arvinas' preclinical AR-V7 program. Arvinas received an aggregate upfront payment of $150.0 million and is eligible for additional development, regulatory and commercial milestones of up to $1.01 billion plus tiered royalties on ARV-766. Novartis assumed responsibility for worldwide clinical development and commercialization of ARV-766 and obtained all research, development, manufacturing and commercialization rights to the preclinical AR-V7 program.
Assessment window: 5yr post-close.
Note: this deal's 5-year assessment window closes ~2029; the outcome grade above is a projected assessment, not yet finalized.
Metastatic castration-resistant prostate cancer is disease that progresses despite androgen deprivation. Resistance is frequently driven by androgen receptor amplification, point mutations and splice variants such as AR-V7, which limit the durability of AR-signalling inhibitors.
Second-generation AR-signalling inhibitors (enzalutamide, abiraterone, apalutamide, darolutamide) act by blocking receptor signalling rather than removing the receptor. PROTAC degraders including ARV-766 and ARV-110 (bavdegalutamide) instead target the AR protein for proteasomal destruction, an approach intended to remain active against ligand-binding-domain mutants. Novartis also competes in this disease with the radioligand Pluvicto.
Arvinas granted Novartis an exclusive worldwide license to ARV-766, a second-generation PROTAC androgen receptor degrader, and sold its preclinical AR-V7 program, for $150M upfront and up to $1.01B in milestones plus tiered royalties.
Arvinas detailed the accounting and contractual terms of the Novartis license and AR-V7 asset purchase in its Q3 2024 quarterly report.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis / Arvinas, Inc. (this deal) | 2024 | $1.2B | 68 |
| Novartis / Isomorphic Labs | 2024 | — | — |
| Novartis / Bristol Myers Squibb | 2017 | — | — |
| Novartis / Surface Oncology | 2016 | — | — |
| Novartis / Vyriad | 2024 | — | — |
| Novartis / Conatus Pharmaceuticals | 2016 | — | — |
| Novartis / Schrödinger | 2024 | — | — |
← Browse all deals · How we score deals
More: 2024 deals · Novartis deals